Having trouble accessing articles? Reset your cache.

ImmunoGen gains on T-DM1 data

ImmunoGen Inc. (NASDAQ:IMGN) gained $0.40 to $7.10 on Friday after reporting data from the Phase II TDM4450g of trastuzumab-DM1 ( T-DM1) for the first-line

Read the full 246 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE